Average Slope vs. Cmax: Which Truly Reflects the Drug-Absorption Rate?

Author:

Kokkali Maria1ORCID,Karalis Vangelis D.12ORCID

Affiliation:

1. Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece

2. Institute of Applied and Computational Mathematics, Foundation for Research and Technology Hellas (FORTH), 70013 Heraklion, Greece

Abstract

Despite ongoing concerns, the primary metric utilized in bioequivalence studies to quantify absorption rate remains the maximum plasma concentration (Cmax). To more accurately depict absorption rate, the concept of “average slope” (AS) has been recently introduced. The objective of this study is to elucidate and compare the characteristics of AS and Cmax in their representation of the drug-absorption rate. For this purpose, an investigation was conducted on five drugs (nintedanib, methylphenidate, nitrofurantoin, lisdexamfetamine, and theophylline) with different absorption and disposition kinetics. The properties of AS and Cmax, as well as their correlations with other pharmacokinetic parameters, were assessed using supervised and unsupervised machine-learning algorithms, namely principal component analysis, random forest, hierarchical cluster analysis, and artificial neural networks. This study showed that, regardless of the absorption kinetics and across every ML algorithm, AS was more sensitive in reflecting the absorption rate compared to Cmax. In all drugs and methods of analysis, AS demonstrated significantly superior performance in expressing the absorption rate compared to Cmax. The joint use of different techniques complemented each other and verified the findings. Moreover, AS can be easily calculated and has the appropriate units and properties to be used as a metric to express the absorption rate in bioequivalence studies. The adoption of AS by regulatory authorities, as an absorption-rate metric, could significantly improve the accuracy and reliability of BE assessments. Overall, this study focused on addressing the longstanding problem of finding an appropriate absorption-rate metric by demonstrating the desirable properties of AS.

Publisher

MDPI AG

Reference55 articles.

1. European Medicines Agency, and Committee for Medicinal Products for Human Use (CHMP) (2024, June 12). Guideline on the Investigation of Bioequivalence; London, UK, 20 January 2010. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf.

2. Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2024, June 12). Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General Considerations, Available online: https://www.fda.gov/media/88254/download.

3. Niazi, S. (2014). Handbook of Bioequivalence Testing (Drugs and the Pharmaceutical Sciences), Taylor & Francis Group. [2nd ed.].

4. Karalis, V. (2016). Modeling and Simulation in Bioequivalence. Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics. Homogeneous and Heterogeneous Approaches, Springer International Publishing.

5. Bioequivalence: Performance of Several Measures of Extent of Absorption;Bois;Pharm. Res.,1994

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3